                         SEQUENCE LISTING

<110>  Wall, Jonathan S
       Foster, Stephan L
       Kennel, Stephen J
 
<120>  Pre-Targeting Immunotherapy for Amyloidosis

<130>  UTK127404.PCT

<160>  25    

<170>  PatentIn version 3.5

<210>  1
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p5

<400>  1

Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln Ala Gln Lys Ala 
1               5                   10                  15      


Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln 
            20                  25      


<210>  2
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p5R

<400>  2

Arg Ala Gln Arg Ala Gln Ala Arg Gln Ala Arg Gln Ala Gln Arg Ala 
1               5                   10                  15      


Gln Arg Ala Gln Ala Arg Gln Ala Arg Gln 
            20                  25      


<210>  3
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p5G

<400>  3

Gly Ala Gln Gly Ala Gln Ala Gly Gln Ala Gly Gln Ala Gln Gly Ala 
1               5                   10                  15      


Gln Gly Ala Gln Ala Gly Gln Ala Gly Gln 
            20                  25      


<210>  4
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p8

<400>  4

Lys Ala Lys Ala Lys Ala Lys Ala Lys Ala Lys Ala Lys Ala Lys 
1               5                   10                  15  


<210>  5
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p9

<400>  5

Lys Ala Gln Ala Lys Ala Gln Ala Lys Ala Gln Ala Lys Ala Gln Ala 
1               5                   10                  15      


Lys Ala Gln Ala Lys Ala Gln Ala Lys Ala Gln Ala Lys 
            20                  25                  


<210>  6
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p20

<400>  6

Lys Ala Gln Gln Ala Gln Ala Lys Gln Ala Gln Gln Ala Gln Lys Ala 
1               5                   10                  15      


Gln Gln Ala Gln Ala Lys Gln Ala Gln Gln 
            20                  25      


<210>  7
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p20

<400>  7

Gln Ala Gln Lys Ala Gln Ala Gln Gln Ala Lys Gln Ala Gln Gln Ala 
1               5                   10                  15      


Gln Lys Ala Gln Ala Gln Gln Ala Lys Gln 
            20                  25      


<210>  8
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p31

<400>  8

Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln Ala Gln Lys Ala 
1               5                   10                  15      


Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln 
            20                  25      


<210>  9
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p37

<400>  9

Lys Thr Val Lys Thr Val Thr Lys Val Thr Lys Val Thr Val Lys Thr 
1               5                   10                  15      


Val Lys Thr Val Thr Lys Val Thr Lys Val 
            20                  25      


<210>  10
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p39

<400>  10

Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln Ala Gln Lys Ala 
1               5                   10                  15      


Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln 
            20                  25      


<210>  11
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p42


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Tyrosine at position 2 is a D-enantiomer

<400>  11

Val Tyr Lys Val Lys Thr Lys Val Lys Thr Lys Val Lys Thr Lys Val 
1               5                   10                  15      


Lys Thr 
        


<210>  12
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p43


<220>
<221>  MISC_FEATURE
<222>  (1)..(3)
<223>  First 3 amino acids are D-enantiomers

<400>  12

Ala Gln Ala Tyr Ser Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys 
1               5                   10                  15      


Gln Ala Gln Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln 
            20                  25                  30      


<210>  13
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p44


<220>
<221>  MISC_FEATURE
<222>  (1)..(3)
<223>  First 3 amino acids are D-enantiomers

<400>  13

Ala Gln Ala Tyr Ala Arg Ala Gln Arg Ala Gln Ala Arg Gln Ala Arg 
1               5                   10                  15      


Gln Ala Gln Arg Ala Gln Arg Ala Gln Ala Arg Gln Ala Arg Gln 
            20                  25                  30      


<210>  14
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p48


<220>
<221>  MISC_FEATURE
<222>  (4)..(31)
<223>  Amino acids 4 through 31 are D-enantiomers

<400>  14

Ala Gln Ala Tyr Ser Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys 
1               5                   10                  15      


Gln Ala Gln Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln 
            20                  25                  30      


<210>  15
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p50

<400>  15

Ala Gln Ala Tyr Ser Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys 
1               5                   10                  15      


Gln Ala Gln Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln 
            20                  25                  30      


<210>  16
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p58


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Tyrosine at fourth position is a D-enantiomer

<400>  16

Ala Gln Ala Tyr Ser Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys 
1               5                   10                  15      


Gln Ala Gln Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln 
            20                  25                  30      


<210>  17
<211>  40
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide p5+14

<400>  17

Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln Ala Gln Lys Ala 
1               5                   10                  15      


Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln Ala Gln Lys Ala Gln Lys 
            20                  25                  30          


Ala Gln Ala Lys Gln Ala Lys Gln 
        35                  40  


<210>  18
<211>  58
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fusion protein between p66 and antibody epitope sequence 11-1F4

<400>  18

Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln Ala Gln Lys Ala 
1               5                   10                  15      


Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln Ala Gln Lys Ala Gln Lys 
            20                  25                  30          


Ala Gln Ala Lys Gln Ala Lys Gln Ser Val Thr Val Val Thr Lys His 
        35                  40                  45              


Tyr Ala Ala Phe Pro Glu Asn Leu Leu Ile 
    50                  55              


<210>  19
<211>  58
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fusion protein of p66 with 11-1F4 antibody epitope including a 
       linker sequence


<220>
<221>  MISC_FEATURE
<222>  (41)..(46)
<223>  X = any amino acid or zero amino acids

<220>
<221>  MISC_FEATURE
<222>  (41)..(46)
<223>  Linker

<400>  19

Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln Ala Gln Lys Ala 
1               5                   10                  15      


Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln Ala Gln Lys Ala Gln Lys 
            20                  25                  30          


Ala Gln Ala Lys Gln Ala Lys Gln Xaa Xaa Xaa Xaa Xaa Xaa Lys His 
        35                  40                  45              


Tyr Ala Ala Phe Pro Glu Asn Leu Leu Ile 
    50                  55              


<210>  20
<211>  72
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Fusion peptide of p66 with antibody epitope sequence and a linker


<220>
<221>  MISC_FEATURE
<222>  (41)..(60)
<223>  X is any amino acid or zero amino acids

<220>
<221>  MISC_FEATURE
<222>  (41)..(60)
<223>  Linker sequence

<400>  20

Lys Ala Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln Ala Gln Lys Ala 
1               5                   10                  15      


Gln Lys Ala Gln Ala Lys Gln Ala Lys Gln Ala Gln Lys Ala Gln Lys 
            20                  25                  30          


Ala Gln Ala Lys Gln Ala Lys Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
        35                  40                  45              


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys His Tyr Ala 
    50                  55                  60                  


Ala Phe Pro Glu Asn Leu Leu Ile 
65                  70          


<210>  21
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Linker sequence

<400>  21

Ser Val Thr Val Val Thr 
1               5       


<210>  22
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Len-based peptide epitope

<400>  22

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


<210>  23
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody epitope sequence 11-1F4

<400>  23

Lys His Tyr Ala Ala Phe Pro Glu Asn Leu Leu Ile 
1               5                   10          


<210>  24
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Functional leader sequence

<400>  24

Gly Gly Gly Tyr Ser 
1               5   


<210>  25
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Functional leader sequence

<400>  25

Cys Gly Gly Tyr Ser 
1               5   


